Japan Vaccine Co. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Japan Vaccine Co. Ltd.
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
Daiichi Sankyo makes further vaccine business restructuring moves as it emphasizes oncology amid global generic challenges to its former big seller olmesartan.
Hot on the heels of the FDA approval, GlaxoSmithKline has received the green light for its shingles vaccine Shingrix from both the EU Commission and the Japanese Ministry of Health, Labour and Welfare but it is remaining tightlipped about its commercialization plans.
Daiichi Sankyo is adding to its vaccines portfolio in Japan through a deal to market in the country AstraZeneca's nasally administered quadrivalent flu product FluMist.